Zacks Investment Research
10 Aug 2026, 18:06 UTC · 9w ago
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
Impact · against what's priced in
ANIP faces a negative catalyst as the market reacts to a revenue miss and lowered outlook for its core Cortrophin Gel product, which outweighs the Q2 earnings beat. HRMY is minimally impacted by its role as a licensing partner contributing to ANIP's royalty revenues.
- ANIP−0.40
No priced-in read yet
- In context
The company lowered its full-year outlook for Cortrophin Gel and missed specific revenue estimates for that product ($117.1M vs $120.4M), triggering a 5% share price drop despite an overall EPS beat of $2.21.
Read from the article alone
Search tags
